Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID)

Accepted/In Press date: 19 August 2021

Published date: 23 September 2021

Additional Information: Funding Information: The UKILD-Long COVID study is a prospective multi-centre observational cohort study that will be managed through the Imperial College National Heart and Lung Institute and funded by the UKRI Medical Research Council and an NIHR professorship (RGJ). The primary study aims to define the prevalence and risk factors for LC-ILD using data from 10 000 stratified patients, collected from the UK’s national PHOSP for COVID platform study, together with 2000 non-hospitalised patients referred for assessment up to 3 months for investigation of persistent respiratory symptoms post-COVID-19, such as breathlessness and cough (figure 1A). These patients will be recruited from Long COVID clinics or community Post-COVID-19 clinical trials (REACT Long COVID Study19). We will assess the clinical and genetic risk factors for post-COVID-19 ILD and radiological classification, as well as the trajectory and pathogenic mechanisms of progression following acute COVID with longitudinal analysis of biomarkers and the undertaking of two substudies (figure 1B). 1. Up to 80 participants will undergo detailed longitudi-nal xenon and proton MRI coupled with measures of flow-mediated endothelial function in the microvascu-lature measured by EndoPat. 2. Up to 50 participants will undergo bronchoscopy with bronchoalveolar lavage (BAL) for single cell and/or bulk RNA sequencing (RNA-seq), with matched flow cytometry analysis, as well as microbiome analysis. Funding Information: Funding The collaborative research programme entitled, The UK Interstitial Lung Disease-Long COVID-19 study (UKILD-Long COVID): understanding the burden of Interstitial Lung Disease in Long COVID is funded by UK Research and Innovation MRC research grant award (grant reference MR/W006111/1). The collaborative research programme entitled PHOSP-COVID Posthospitalisation COVID-19 study: a national consortium to understand and improve long-term health outcomes is jointly funded by UK Research and Innovation and National Institute of Health Research (grant references: MR/V027859/1 and COV0319 and ISRCTN number 10980107). In addition, PM is supported by MRC—GlaxoSmithKline GSK Experimental Medicine and co-funding NIHR University College London Hospitals Biomedical Research Centre. JB is supported by MRC transition award (MR/ T032529/1). BG is funded by MRC-UK, the British Lung Foundation, The Alpha-1 Foundation and supported by the NIHR Leicester Biomedical Research Centre. IPH is supported by an NIHR Senior Investigator Award. SRJ is supported by Nottingham NIHR BRC. PLM is supported by an Action for Pulmonary Fibrosis Mike Bray fellowship. AART is supported by a British Heart Foundation Intermediate Clinical Fellowship (FS/18/13/3328). L-PH is supported by the NIHR Oxford Biomedical Research Centre. JJ is supported by a Wellcome Trust Clinical Research Career Development Fellowship (209553/Z/17/Z) and the NIHR UCLH Biomedical Research Centre, UK. LW holds a GSK/British Lung Foundation Chair in Respiratory Research (C17-1). The research was partially supported by the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre. RGJ is supported by an NIHR Research Professorship (RP-2017-08-ST2-014). AJS is a National Institute for Health Research (NIHR) Senior Investigator. Disclaimer The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. Competing interests None declared. Publisher Copyright: ©

Keywords: COVID-19/complications, Humans, Longitudinal Studies, Lung Diseases, Interstitial/epidemiology, Observational Studies as Topic, Pandemics, Prospective Studies, United Kingdom/epidemiology

Local EPrints ID: 453657

URI: http://eprints.soton.ac.uk/id/eprint/453657

DOI: doi:10.1136/bmjresp-2021-001049

ISSN: 2052-4439

PURE UUID: 80baa571-3a99-471e-8f1b-f1091936aad2

ORCID for Mark G Jones: orcid.org/0000-0001-6308-6014

Date deposited: 20 Jan 2022 17:44

Last modified: 17 Mar 2024 03:12